Recent Company News

• 09:15 AM ET Jul 09, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 09:04 AM ET Jul 09, 2025
  

  Connect Biopharma Holdings issues press release on Simcere Pharmaceutical's submission of its NDA for rademikibart for the treatment of atopic dermatitis in China ($1.13, 0.00)

• 12:28 AM ET Jul 08, 2025
  

  China NMPA accepts NDA for Simcere Pharmaceutical Group's rademikibart for treatment of atopic dermatitis in adults and adolescents (HK$10.50, -0.08)

• 09:04 AM ET Jun 13, 2025
  

  Connect Biopharma presents data on rademikibart at EAACI 2025 Annual Congress ($0.85, 0.00)

• 04:48 PM ET Jun 12, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:37 AM ET Jun 12, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:06 AM ET Jun 12, 2025
  

  Connect Biopharma Holdings assumed buy at HC Wainwright; prior rating was buy ($0.82, 0.00)

• 04:38 PM ET Jun 10, 2025
  

  Connect Biopharma files $300M mixed securities shelf; enters into ADS sales agreement for up to $150M with Cantor Fitzgerald - F-3 ($0.80, 0.00)

• 09:05 AM ET May 20, 2025
  

  Connect Biopharma presents data on rademikibart at the American Thoracic Society (ATS) 2025 International Conference ($0.78, 0.00)

• 09:04 AM ET May 15, 2025
  

  Connect Biopharma Holdings reports Q1 net income (CNY10.3M) vs year-ago (CNY8.7M) ($0.77, 0.00)